Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM2BP4_Moderate
The NM_007294.4(BRCA1):c.3587C>T(p.Thr1196Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,614,094 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM1
In a compositionally_biased_region Polar residues (size 15) in uniprot entity BRCA1_HUMAN there are 8 pathogenic changes around while only 1 benign (89%) in NM_007294.4
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.11410743).
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:5
Uncertain significance, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Mar 31, 2016
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Counsyl
Jun 13, 2017
- -
Uncertain significance, no assertion criteria provided
clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center
May 05, 2023
A variant of uncertain significance was detected in this sample , This sequence change replaces threonine with isoleucine at codon 1196 of the BRCA1 protein (p.Thr1196Ile). The threonine residue is moderately conserved and there is a moderate physicochemical difference between threonine and isoleucine. This variant is not present in population databases (GenomAD). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 24372583, 27211102, 29297111). ClinVar contains an entry for this variant (Variation ID: 54926). Ten ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as "uncertain significance.". In addition, this alteration is predicted to be tolerated by in silico analysis. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, no assertion criteria provided
clinical testing
Breast Cancer Information Core (BIC) (BRCA1)
Nov 25, 2004
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Illumina Laboratory Services, Illumina
Apr 27, 2017
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter
clinical testing
CeGaT Center for Human Genetics Tuebingen
Aug 01, 2019
- -
Uncertain significance, criteria provided, single submitter
clinical testing
GeneDx
Dec 12, 2024
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as 3706C>T; This variant is associated with the following publications: (PMID: 24372583, 27211102, 26295337, 29297111, 10923033, 23704879, 34646395, 31131967, 29884841, 35402282, 32377563, 37335020, 35171259) -
Uncertain significance, criteria provided, single submitter
Likely benign, criteria provided, single submitter
curation
University of Washington Department of Laboratory Medicine, University of Washington
Mar 23, 2023
Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
Uncertain significance, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Mar 22, 2023
This missense variant replaces threonine with isoleucine at codon 1196 of the BRCA1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in 5 individuals affected with breast or ovarian cancer (PMID: 24372583, 29297111, 34646395, 35402282). This variant has been identified in 1/250882 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, additional functional studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance -
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Sep 21, 2024
The p.T1196I variant (also known as c.3587C>T), located in coding exon 9 of the BRCA1 gene, results from a C to T substitution at nucleotide position 3587. The threonine at codon 1196 is replaced by isoleucine, an amino acid with similar properties. This variant has been reported in multiple individuals with features consistent with BRCA1-related cancer predisposition (Riahi A et al. Clin Genet, 2015 Feb;87:155-60; Alhuqail AJ et al. Breast Cancer Res Treat, 2018 Apr;168:695-702; Laraqui A et al. J Genomics, 2021 Sep;9:43-54; Khandakji M et al. Physiol Genomics, 2023 Aug;55:315-323; Yin L et al. JAMA Netw Open, 2022 Feb;5:e2148721; Abdel-Razeq H et al. Front Oncol, 2022 Mar;12:673094). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Oct 11, 2022
Variant summary: BRCA1 c.3587C>T (p.Thr1196Ile) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250882 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3587C>T, has been reported in the literature in an individual affected with Breast and/or Ovarian Cancer (example, Riahi_2015, Riahi_2016). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Uncertain significance, criteria provided, single submitter
clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Feb 06, 2024
- -
BRCA1-related cancer predisposition Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
All of Us Research Program, National Institutes of Health
Apr 16, 2024
This missense variant replaces threonine with isoleucine at codon 1196 of the BRCA1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in 5 individuals affected with breast or ovarian cancer (PMID: 24372583, 29297111, 34646395, 35402282). This variant has been identified in 1/250882 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, additional functional studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance -
BRCA1-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
PreventionGenetics, part of Exact Sciences
Feb 23, 2023
The BRCA1 c.3587C>T variant is predicted to result in the amino acid substitution p.Thr1196Ile. This variant has been reported in individuals with breast and/or ovarian cancer (Table 2, Riahi et al. 2015. PubMed: 24372583; Table 4, Riahi et al. 2016. PubMed ID: 27211102; Table S5, Alhuqail et al. 2018. PubMed ID: 29297111; Table 4, Laraqui et al. 2021. PubMed ID: 34646395). This variant is reported in 1 of ~251,000 alleles in gnomAD (http://gnomad.broadinstitute.org/variant/17-41243961-G-A). It is interpreted as uncertain significance in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/54926/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hereditary breast ovarian cancer syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Jan 19, 2024
This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 1196 of the BRCA1 protein (p.Thr1196Ile). This variant is present in population databases (rs80356944, gnomAD 0.0009%). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 24372583, 27211102, 29297111, 34646395, 35171259). ClinVar contains an entry for this variant (Variation ID: 54926). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -